Neutropenia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Neutropenia – Pipeline Review, H1 2017’, provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neutropenia

– The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects

– The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neutropenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neutropenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adello Biologics LLC

Apotex Inc

Arven Ilac

BeyondSpring Pharmaceuticals Inc

Cellerant Therapeutics Inc

Cleveland BioLabs Inc

Coherus BioSciences Inc

Dr. Reddy's Laboratories Ltd

Eurofarma Laboratorios SA

Intas Pharmaceuticals Ltd

Ligand Pharmaceuticals Inc

Lupin Ltd

Mycenax Biotech Inc

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neutropenia - Overview

Neutropenia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Neutropenia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neutropenia - Companies Involved in Therapeutics Development

Adello Biologics LLC

Apotex Inc

Arven Ilac

BeyondSpring Pharmaceuticals Inc

Cellerant Therapeutics Inc

Cleveland BioLabs Inc

Coherus BioSciences Inc

Dr. Reddy's Laboratories Ltd

Eurofarma Laboratorios SA

Intas Pharmaceuticals Ltd

Ligand Pharmaceuticals Inc

Lupin Ltd

Mycenax Biotech Inc

Prolong Pharmaceuticals LLC

Richter Gedeon Nyrt

Sandoz International GmbH

USV Pvt Ltd

Neutropenia - Drug Profiles

ACN-8337 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARVMIC-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBLB-612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LG-7455 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plinabulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romyelocel-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tamibarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neutropenia - Dormant Projects

Neutropenia - Product Development Milestones

Featured News & Press Releases

Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar

Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention

Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo

Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)

Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO

Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case

Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case

Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study

May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication

Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets

Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim

Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study

Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701

Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program

Dec 07, 2015: Phase III Data Shows Sandoz’ Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Neutropenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neutropenia – Pipeline by Adello Biologics LLC, H1 2017

Neutropenia – Pipeline by Apotex Inc, H1 2017

Neutropenia – Pipeline by Arven Ilac, H1 2017

Neutropenia – Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017

Neutropenia – Pipeline by Cellerant Therapeutics Inc, H1 2017

Neutropenia – Pipeline by Cleveland BioLabs Inc, H1 2017

Neutropenia – Pipeline by Coherus BioSciences Inc, H1 2017

Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017

Neutropenia – Pipeline by Eurofarma Laboratorios SA, H1 2017

Neutropenia – Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Neutropenia – Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Neutropenia – Pipeline by Lupin Ltd, H1 2017

Neutropenia – Pipeline by Mycenax Biotech Inc, H1 2017

Neutropenia – Pipeline by Prolong Pharmaceuticals LLC, H1 2017

Neutropenia – Pipeline by Richter Gedeon Nyrt, H1 2017

Neutropenia – Pipeline by Sandoz International GmbH, H1 2017

Neutropenia – Pipeline by USV Pvt Ltd, H1 2017

Neutropenia – Dormant Projects, H1 2017

Neutropenia – Dormant Projects, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development for Neutropenia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports